Prognostic value of platelet to lymphocyte ratio in predicting survival of patients with metastatic castration‐resistant prostate cancer receiving abiraterone acetate: An evidence‐based case report and review of literature.
- Resource Type
- Article
- Authors
- Yausep, Oliver E.; Agarwal, Raksheeth; Aulina, Rifqha; Wijaya, Anthony E.; Amaia, Ilonka; Moekti, Addina W.; Rinaldi, Ikhwan; Hamid, Agus Rizal A. H.
- Source
- Clinical Case Reports. Aug2019, Vol. 7 Issue 8, p1585-1590. 6p.
- Subject
- *CASTRATION-resistant prostate cancer
*ABIRATERONE acetate
*LYMPHOCYTES
*LITERATURE reviews
*PROSTATE cancer patients
- Language
- ISSN
- 2050-0904
Platelet to lymphocyte ratio (PLR) is a candidate prognostic marker for metastatic castration‐resistant prostate cancer patients receiving abiraterone acetate and evidence demonstrates that a high PLR is associated with poor survival. More studies are required to verify current findings and establish a definite cutoff point. [ABSTRACT FROM AUTHOR]